The complaint filed in the U.S. District Court for the Northern District of California claims that Doximity touted record engagement figures while failing to disclose that its core advertising methods were losing ground to programmatic and social formats. Plaintiffs argue that the company's reliance on a proprietary cost-per-target revenue structure masked a shift in pharmaceutical spending habits, leading to three significant stock declines that erased a total of $19.26 per share. By the final drop on May 14, 2026, the company’s stock had fallen to $18.01.

Legal counsel Joseph E. Levi contends that Doximity’s reliance on boilerplate risk disclosures failed to address specific, known pressures on its business model. The lawsuit names key executives as defendants, including CEO Jeffrey Tangney, CFO Anna Bryson, and Chief Strategy Officer Nate Gross. Investors holding shares during the specified class period are encouraged to review their brokerage records and evaluate potential claims before the court-mandated deadline.